

CANDIDATURA ALLA PRESIDENZA

Società Italiana per lo Studio delle Cefalee (SISC)

Prof. Antonio Russo

La candidatura alla Presidenza della SISC nasce dalla volontà di mettere al servizio della Società un percorso costruito nell'assistenza alle persone con cefalea, nella ricerca scientifica, nella formazione e nell'organizzazione sanitaria, con una consolidata proiezione nazionale e internazionale nell'ambito dell'headache medicine.

Professore Ordinario Neurologia - Università della Campania "Luigi Vanvitelli"	Direttore Programma Interdipartimentale di Medicina delle Cefalee e delle Sindromi Dolorose Primarie presso A.O.U. "Luigi Vanvitelli"	Produzione scientifica Oltre 230 pubblicazioni - H-index 43
Ultimi 5 anni 76 contributi scientifici documentati	Ricerca clinica Oltre 50 trial di fase 3 e 4 sull'emicrania	Ricerca competitiva Responsabile PRIN 2015 e PRIN 2022

Profilo accademico e clinico

Antonio Russo è Professore Ordinario di Neurologia presso l'Università degli Studi della Campania "Luigi Vanvitelli" dal dicembre 2023. Laureato in Medicina e Chirurgia nel 2003 con 110/110 e lode, ha conseguito la Specializzazione in Neurologia nel 2009 con 50/50 e lode e, nel 2013, il Dottorato di Ricerca in Fisiopatologia Sperimentale e Neuroscienze, con una tesi dedicata all'impiego della BOLD-fMRI nello studio dei meccanismi fisiopatologici dell'emicrania.

Svolge attività clinica presso il Programma Interdipartimentale di Medicina delle Cefalee e delle Sindromi Dolorose Primarie dell'Azienda Ospedaliera Universitaria "Luigi Vanvitelli" di Napoli, di cui è Direttore. Il Centro è riconosciuto dalla SISC come "Centro di III Livello per la Diagnosi e Cura delle Cefalee dell'Adulto con Attività di Ricerca e Didattica".

Ricerca, innovazione e leadership scientifica

La sua attività scientifica è prevalentemente dedicata alla fisiopatologia, al neuroimaging e al trattamento delle cefalee, con particolare interesse per l'emicrania con e senza aura, il dolore trigeminale, la connettività cerebrale e i biomarcatori di neuroimaging. Dal 2009 svolge attività scientifica presso il Centro per Studi di Risonanza Magnetica ad Alto Campo dell'Ateneo "Luigi Vanvitelli" di Napoli.

È stato responsabile del progetto PRIN 2015 "Searching for bio-morpho-functional markers of the migraine brain" e del progetto PRIN 2022 "Exploring the effects of lamotrigine on interictal neurovascular coupling within visual network in patients with migraine with aura: a multiparametric longitudinal study with EEG-fMRI and multi-delay 3D-pseudocontinuous arterial spin labelling".

Ha svolto e svolge attività di Principal Investigator in studi clinici di fase 3 e 4 per la terapia dell'emicrania e ha partecipato a oltre 50 trial di fase 3 e 4 dedicati a nuove terapie per l'emicrania. Ha presentato numerosi contributi scientifici a congressi nazionali e internazionali, in qualità di relatore o moderatore, tra cui SISC, SIN, EHF, IHS ed EAN, ed è stato invitato a tenere lecture presso European Headache Federation, American Headache Society e American Academy of Neurology.

Tra i principali riconoscimenti figurano il “Greppi Award 2019” della European Headache Federation e il “Wolff Award” dell’American Headache Society, conferiti per l’attività di ricerca nell’ambito delle cefalee e, in particolare, per gli studi condotti mediante tecniche avanzate di neuroimaging. È Chief Editor di *Frontiers in Neurology*, sezione Headache Medicine and Facial Pain, e Deputy Editor di *Confinia Cephalalgia*; svolge inoltre attività di revisore per numerose riviste internazionali, tra cui *Neurology*, *Headache*, *Cephalalgia*, *Pain Medicine*, *Journal of Neurology* e *Neurological Sciences*. A questa attività affianca un costante impegno nella divulgazione scientifica sulle cefalee attraverso media, social network e pubblicazioni divulgative.

Impegno nella SISC e attività istituzionale

Nell’ambito della Società Italiana per lo Studio delle Cefalee ha ricoperto incarichi nel Consiglio Direttivo Nazionale e, all’interno del Centro Studi SISC, i ruoli di Vice-Responsabile e successivamente di Responsabile. Ha inoltre partecipato regolarmente all’attività didattica della Scuola Superiore per le Cefalee della SISC, con relazioni dedicate al neuroimaging convenzionale e avanzato, alla fisiopatologia dell’emicrania e delle cefalee autonomico-trigeminali e alle terapie preventive e della fase acuta.

È attualmente consigliere nel Consiglio Direttivo Nazionale della Società Italiana di Neurologia (SIN) ed è stato membro dell’Headache Panel della European Academy of Neurology in rappresentanza della SIN. È inoltre responsabile per la Regione Campania del progetto “Linee di indirizzo per la realizzazione dei progetti regionali finalizzati a sperimentare metodi innovativi di presa in carico delle persone affette da cefalea primaria cronica”, di cui al Decreto n. 17 del 23 marzo 2023 del Ministero della Salute.

Profilo della candidatura

La candidatura intende mettere questa esperienza clinica, scientifica, formativa e istituzionale al servizio della SISC, con l’obiettivo di rafforzarne ulteriormente il ruolo quale riferimento nazionale per la ricerca, la formazione, l’assistenza e la cultura delle cefalee, valorizzando il contributo dei Centri, dei soci e delle nuove generazioni e consolidando la presenza della Società nel panorama scientifico nazionale e internazionale.

Produzione scientifica negli ultimi cinque anni

È autore di oltre 230 pubblicazioni scientifiche (H-index 43). Nel periodo agosto 2021 - agosto 2026 sono documentati 76 contributi scientifici, riportati integralmente di seguito.

2026

1. Patient depressive symptoms and reciprocity are associated with distress in the caregiver of patients with migraine: insights from the MI-DEAR observational cohort study. *The Journal of Headache and Pain*. August 2026.
2. Sex-related differences in striatal functional connectivity in early Parkinson’s disease. *npj Parkinson’s Disease*. August 2026.
3. Effectiveness of Onabotulinumtoxin-A in Patients with Chronic Migraine and Previous CGRP-mAb Treatment Failure: A Multicentre 6-Month Real-World Experience. *Toxins*. August 2026.
4. SafeTy and effectiveness of Atogepant according to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study). *Cephalalgia*. June 2026.
5. The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies. *Headache: The Journal of Head and Face Pain*. June 2026.
6. The Relevance of Crystal Clear and Unclear Days to Evaluate Residual Interictal Burden in Patients With Migraine Treated With CGRP Monoclonal Antibodies. *European Journal of Neurology*. April 2026.
7. Translation and validation of the Migraine Interictal Burden Scale (MIBS-4) in an Italian clinical cohort. *Neurological Sciences*. April 2026.
8. The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerability. *Cephalalgia*. March 2026.
9. Subcortical microstructural impairment in amyotrophic lateral sclerosis: clinical correlates of neurite orientation dispersion and density imaging (NODDI) changes. *Frontiers in Neuroscience*. February 2026.
10. Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study). *Cephalalgia*. February 2026.

2025

11. Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study). *Therapeutic Advances in Neurological Disorders*. December 2025.
12. Moderate to Severe Acute Migraine Attacks: An Opinion Paper on the Use of Triptans and Triptan-NSAIDs Combinations in Individualized Treatment Plans. *Neurology and Therapy*. December 2025.

13. Combination preventive therapy with onabotulinumtoxinA and atogepant for chronic migraine: A 24-week, prospective, real-world evaluation (SYNERGY study). *Cephalalgia*. December 2025.
14. Response to the Letter by Tfelt-Hansen and Hougaard "Some observed problems of the evidence presented for zolmitriptan nasal spray in the 'Evidence-Based Recommendations of Pharmacological Treatment of Migraine Attacks'". *Cephalalgia*. November 2025.
15. Sex differences in the clinical features of 2,841 patients with migraine: a post-hoc, multicenter, cross-sectional study. *Frontiers in Neurology*. September 2025.
16. Effectiveness and tolerability of atogepant as preventive treatment in resistant individuals with chronic migraine: Six-month real-world evidence. *Cephalalgia*. August 2025.
17. A case of rapidly progressive juvenile amyotrophic lateral sclerosis associated with a pathogenetic heterozygous de novo variant in the FUS gene. *Neurological Sciences*. June 2025.
18. No additional benefit with detoxification strategies: A real world experience in 200 patients with chronic migraine and either simple or complex MOH treated with CGRP monoclonal antibodies. *Cephalalgia*. June 2025.
19. Topiramate and Kidney Protection: A Serendipitous Connection? *Kidney International Reports*. June 2025.
20. Raising the bar in migraine prevention: Toward freedom and optimal control. *Cephalalgia*. May 2025.
21. Evidence-based guidelines for the pharmacological treatment of migraine. *Cephalalgia*. April 2025.
22. Evidence-based guidelines for the pharmacological treatment of migraine, summary version. *Cephalalgia*. April 2025.
23. Safety of Onabotulinumtoxin-A for Chronic Migraine During Pregnancy and Breastfeeding: A Narrative Review. *Toxins*. April 2025.
24. The relevance of cortical thickness in migraine sufferers and implications to therapy. *Expert Review of Neurotherapeutics*. April 2025.
25. Screening of visuospatial abilities in amyotrophic lateral sclerosis (ALS): a pilot study using the battery for visuospatial abilities (BVA). *Orphanet Journal of Rare Diseases*. March 2025.
26. Switching between anti-CGRP monoclonal antibodies in migraine prophylaxis. *Expert Review of Neurotherapeutics*. January 2025.
27. Perceived ease-of-usability and local tolerability using CGRP monoclonal antibody autoinjectors vs. syringes: an online questionnaire-based study in patients with migraine. *Confinia Cephalgica*. January 2025.
28. Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study). *The Journal of Headache and Pain*. January 2025.

2024

29. Exploring the multifaceted characteristics of aura in migraine: A multicenter, cross-sectional study. *Cephalalgia*. November 2024.
30. Brain neurovascular coupling in amyotrophic lateral sclerosis: Correlations with disease progression and cognitive impairment. *European Journal of Neurology*. November 2024.
31. Agreement of Cerebral Blood Flow Estimates for Large-Scale Cortical Networks Across Multiple Resolution Parcellations. 2024 IEEE International Conference on Metrology for eXtended Reality, Artificial Intelligence and Neural Engineering (MetroXRaine). October 2024.
32. Reduced neurovascular coupling of the visual network in migraine patients with aura as revealed with arterial spin labeling MRI: is there a demand-supply mismatch behind the scenes? *The Journal of Headache and Pain*. October 2024.
33. Sumatriptan-naproxen sodium in migraine: A review. *European Journal of Neurology*. September 2024.
34. Association of anti-calcitonin gene-related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study. *European Journal of Neurology*. September 2024.
35. Altered domain-specific striatal functional connectivity in patients with Parkinson's disease and urinary symptoms. *Journal of Neural Transmission*. April 2024.
36. Dihydroergotamine mesylate nasal spray: an acute treatment option for migraine in adults. *Expert Review of Neurotherapeutics*. April 2024.
37. The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectiveness. *Neurological Sciences*. March 2024.
38. Monoclonal antibodies targeting the calcitonin gene-related peptide pathway improve the effectiveness of acute medication—a real-world study. *Neurological Sciences*. February 2024.
39. Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY). *Neurology and Therapy*. February 2024.

2023

40. Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study. *CNS Drugs*. November 2023.
41. Intrinsic brain functional connectivity predicts treatment-related motor complications in early Parkinson's disease patients. *Journal of Neurology*. October 2023.
42. The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN). *Journal of Neurology*. August 2023.
43. Migraine Treatment: Towards New Pharmacological Targets. *International Journal of Molecular Sciences*. July 2023.
44. Cognitive, behavioral, and brain functional connectivity correlates of fatigue in amyotrophic lateral sclerosis. *Brain and Behavior*. June 2023.
45. Arterial spin labeling MRI applied to migraine: current insights and future perspectives. *The Journal of Headache and Pain*. June 2023.

46. Memory Phenotypes In Early, De Novo Parkinson's Disease Patients with Mild Cognitive Impairment. *Movement Disorders*. June 2023.
47. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials. *Expert Opinion on Emerging Drugs*. April 2023.
48. Effectiveness and safety of CGRP monoclonal antibodies in migraine related to mitochondrial diseases in patients with NARP and PEO syndromes. *Clinical Neurology and Neurosurgery*. March 2023.
49. Infodemiology of cluster headache seasonality: A proof of concept by a Google Trends analysis. *Headache: The Journal of Head and Face Pain*. January 2023.

2022

50. Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study. *Toxins*. December 2022.
51. Resting-state network connectivity changes in drug-naïve Parkinson's disease patients with probable REM sleep behavior disorder. *Journal of Neural Transmission*. December 2022.
52. Galcanezumab effect on "whole pain burden" and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience. *The Journal of Headache and Pain*. December 2022.
53. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. *The Journal of Headache and Pain*. December 2022.
54. Resting state fMRI analysis of pseudobulbar affect in Amyotrophic Lateral Sclerosis (ALS): motor dysfunction of emotional expression. *Brain Imaging and Behavior*. November 2022.
55. OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study. *Journal of Neurology*. November 2022.
56. Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors. *International Journal of Environmental Research and Public Health*. September 2022.
57. Psychological Support for Family Caregivers of Patients With Amyotrophic Lateral Sclerosis at the Time of the Coronavirus Disease 2019 Pandemic: A Pilot Study Using a Telemedicine Approach. *Frontiers in Psychiatry*. June 2022.
58. Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot study. *Cephalalgia*. April 2022.
59. Cluster headache pathophysiology: What we have learned from advanced neuroimaging. *Headache: The Journal of Head and Face Pain*. March 2022.
60. Telemedicine application to headache: a critical review. *Neurological Sciences*. January 2022.

2021

61. Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men. *Frontiers in Neurology*. December 2021.
62. Headache Worsening after COVID-19 Vaccination: An Online Questionnaire-Based Study on 841 Patients with Migraine. *Journal of Clinical Medicine*. December 2021.
63. Between-sex variability of resting state functional brain networks in amyotrophic lateral sclerosis (ALS). *Journal of Neural Transmission*. December 2021.
64. Disconnectome of the migraine brain: a "connectopathy" model. *The Journal of Headache and Pain*. December 2021.
65. Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. *The Journal of Headache and Pain*. December 2021.
66. Enlarging the spectrum of cluster headache: Extracranial autonomic involvement revealed by voice analysis. *Headache: The Journal of Head and Face Pain*. October 2021.
67. Looking for the identikit of refractory chronic migraine patients in the CGRP-monoclonal antibodies scenario: Insight from the real-world experience. *Journal of the Neurological Sciences*. October 2021.
68. Multiple sclerosis functional composite predicts thalamic atrophy in multiple sclerosis. *Journal of the Neurological Sciences*. October 2021.
69. A 67-year-old woman with recurrent headache, migratory focal symptoms, and impaired consciousness. *Journal of the Neurological Sciences*. October 2021.
70. Correlates of psychological distress in epileptic patients during the COVID-19 outbreak. *Journal of the Neurological Sciences*. October 2021.
71. Challenging diagnosis of juvenile amyotrophic lateral sclerosis FUS-related during COVID-19 pandemic. *Journal of the Neurological Sciences*. October 2021.
72. Effectiveness and safety of CGRP-mAbs in menstrual related migraine: A real-world experience. *Journal of the Neurological Sciences*. October 2021.
73. Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients. *Pain and Therapy*. September 2021.
74. The psychological correlates of fatigue in Parkinson's disease: Contribution of maladaptive metacognitive beliefs. *Parkinsonism & Related Disorders*. September 2021.
75. Correlates of the discrepancy between objective and subjective cognitive functioning in non-demented patients with Parkinson's disease. *Journal of Neurology*. September 2021.
76. Functional connectivity changes in complex migraine aura: beyond the visual network. *European Journal of Neurology*. August 2021.

Prof. Antonio Russo